Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376331 | 0.83 | MEN1 (0.65) | SMN1; SMN2KMT2AHPGDALDH1A1LMNA | |
| SCHEMBL29449332 | 0.82 | GSTP1 (0.47) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL7002851 | 0.81 | KMT2A (0.50) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL5795803 | 0.81 | KMT2A (0.71) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL13457196 | 0.81 | ALDH1A1 (0.43) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL9833015 | 0.79 | HPGD (0.48) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL15616677 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL8349572 | 0.79 | ALDH1A1 (0.44) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL6901685 | 0.78 | MEN1 (0.49) | SMN1; SMN2KMT2AHPGDALDH1A1LMNA | |
| SCHEMBL28070730 | 0.78 | ALDH1A1 (0.58) | SMN1; SMN2KMT2ANPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188104-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188104-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2203431-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LAB (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | SMN1; SMN2 4700/4885KMT2A 4704/4885NPC1 188/4885 |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | SMN1; SMN2 4700/4885KMT2A 4704/4885NPC1 188/4885 |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | SMN1; SMN2 4700/4885KMT2A 4704/4885NPC1 188/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | SMN1; SMN2 4700/4885KMT2A 4704/4885NPC1 188/4885 |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | MPO, ELANE, LPO | SMN1; SMN2 4666/4885KMT2A 4715/4885NPC1 188/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | SMN1; SMN2 4700/4885KMT2A 4704/4885NPC1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.